Charles River Laboratories International (CRL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $300.15, -1.99% vs the prior close of $306.24.
- Volume 674.57K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CRL dips 2.0% to $300.15. Closed at $300.15, -1.99% vs the prior close of $306.24. Day range $296.35–$308.46, opened at $306.09.
CRL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CRL dips 2.0% to $300.15
- Closed at $300.15, -1.99% vs the prior close of $306.24. Day range $296.35–$308.46, opened at $306.09.
- Volume was 674.57K shares, 0.7x its 50-day average of 955.84K.
- Price is +3.9% vs its 50-day average ($288.88) and +39.5% vs its 200-day average ($215.10).
- 52-week range $146.20–$333.30; today's close sits at 82% of that range, 9.9% below the 52-week high.
Oct 15, 2026 — CRL rises 1.4% to $306.24
- Closed at $306.24, +1.40% vs the prior close of $302.00. Day range $295.40–$309.48, opened at $301.81.
- Volume was 928.40K shares, 1.0x its 50-day average of 972.92K.
- Price is +6.3% vs its 50-day average ($288.19) and +42.7% vs its 200-day average ($214.61).
- 52-week range $146.20–$333.30; today's close sits at 86% of that range, 8.1% below the 52-week high.
Oct 14, 2026 — CRL rises 1.0% to $302.00
- Closed at $302.00, +1.00% vs the prior close of $299.02. Day range $296.00–$310.53, opened at $297.53.
- Volume was 941.30K shares, 1.0x its 50-day average of 977.03K.
- Price is +5.1% vs its 50-day average ($287.28) and +41.1% vs its 200-day average ($214.09).
- 52-week range $146.20–$333.30; today's close sits at 83% of that range, 9.4% below the 52-week high.
Oct 13, 2026 — CRL dips 0.9% to $299.02
- Closed at $299.02, -0.94% vs the prior close of $301.86. Day range $295.15–$302.77, opened at $301.00.
- Volume was 753.30K shares, 0.8x its 50-day average of 974.12K.
- Price is +4.6% vs its 50-day average ($285.92) and +40.0% vs its 200-day average ($213.60).
- 52-week range $146.20–$333.30; today's close sits at 82% of that range, 10.3% below the 52-week high.
Oct 12, 2026 — CRL ends flat (+0.0%) to $301.86
- Closed at $301.86, +0.02% vs the prior close of $301.79. Day range $299.27–$303.10, opened at $301.80.
- Volume was 543.80K shares, 0.6x its 50-day average of 973.43K — lighter than usual.
- Price is +6.1% vs its 50-day average ($284.56) and +41.6% vs its 200-day average ($213.12).
- 52-week range $146.20–$333.30; today's close sits at 83% of that range, 9.4% below the 52-week high.
Oct 9, 2026 — CRL rises 1.3% to $301.79
- Closed at $301.79, +1.27% vs the prior close of $298.00. Day range $294.60–$305.21, opened at $294.60.
- Volume was 679.80K shares, 0.7x its 50-day average of 978.59K.
- Price is +6.6% vs its 50-day average ($283.17) and +41.9% vs its 200-day average ($212.62).
- 52-week range $146.20–$333.30; today's close sits at 83% of that range, 9.5% below the 52-week high.
Oct 8, 2026 — CRL dips 0.8% to $298.00, 3 down days in a row
- Closed at $298.00, -0.77% vs the prior close of $300.30. Day range $288.43–$298.27, opened at $297.01.
- Volume was 1.18M shares, 1.2x its 50-day average of 976.14K.
- Price is +5.7% vs its 50-day average ($281.83) and +40.5% vs its 200-day average ($212.13).
- 52-week range $146.20–$333.30; today's close sits at 81% of that range, 10.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — CRL dips 1.5% to $300.30
- Closed at $300.30, -1.53% vs the prior close of $304.96. Day range $294.28–$305.18, opened at $303.38.
- Volume was 1.24M shares, 1.3x its 50-day average of 976.45K.
- Price is +7.0% vs its 50-day average ($280.56) and +41.9% vs its 200-day average ($211.63).
- 52-week range $146.20–$333.30; today's close sits at 82% of that range, 9.9% below the 52-week high.
Oct 6, 2026 — CRL dips 1.9% to $304.96 on 2.0x normal volume
- Closed at $304.96, -1.87% vs the prior close of $310.77. Day range $300.01–$333.30, opened at $319.80.
- Volume was 1.92M shares, 2.0x its 50-day average of 952.40K — unusually heavy trading.
- Price is +9.2% vs its 50-day average ($279.36) and +44.5% vs its 200-day average ($211.09).
- 52-week range $146.20–$333.30; today's close sits at 85% of that range, 8.5% below the 52-week high.
Oct 5, 2026 — CRL jumps 7.1% to $310.77, a 52-week high
- Closed at $310.77, +7.09% vs the prior close of $290.19. Day range $292.02–$312.26, opened at $292.05.
- Volume was 1.31M shares, 1.4x its 50-day average of 935.81K.
- Price is +11.9% vs its 50-day average ($277.75) and +47.6% vs its 200-day average ($210.55).
- 52-week range $146.20–$312.26; today's close sits at 99% of that range, 0.5% below the 52-week high.
Oct 2, 2026 — CRL rises 1.2% to $290.19
- Closed at $290.19, +1.17% vs the prior close of $286.83. Day range $285.75–$290.61, opened at $287.91.
- Volume was 443.50K shares, 0.5x its 50-day average of 948.44K — lighter than usual.
- Price is +5.1% vs its 50-day average ($276.07) and +38.2% vs its 200-day average ($209.97).
- 52-week range $146.20–$303.31; today's close sits at 92% of that range, 4.3% below the 52-week high.
CRL latest news & SEC filings
Every SEC filing by or about CRL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Parisotto Shannon M converted options/RSUs into 981 shares at $208.44 (≈$204.48K) on Oct 5, 2026; now holds 5,788
- Parisotto Shannon M sold 981 shares at $308.44 (≈$302.58K) on Oct 5, 2026; now holds 4,807
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Coleman Glenn bought 10 shares at $297.43 (≈$2.97K) on Sep 30, 2026; now holds 27,762
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Foster James C sold 33,561 shares at $300.00 (≈$10.07M) on Aug 25, 2026
- Foster James C sold 33,561 shares at $300.00 (≈$10.07M) on Aug 25, 2026
- Foster James C sold 33,561 shares at $300.00 (≈$10.07M) on Aug 25, 2026
- Foster James C sold 33,561 shares at $300.00 (≈$10.07M) on Aug 25, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 25, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 27, 2026:
- Revenue: $1.00B (prior year $1.03B) (-2.7% vs Jun 28, 2025)
- Net income: -$1.48M (prior year $52.33M) (loss widened vs Jun 28, 2025)
- Diluted EPS: -$0.03 (prior year $1.06) (loss widened vs Jun 28, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade CRL
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 18, 2026, Jan 13, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.76% (largest 7.1%).
- Liquidity: about 995.21K shares (≈$298.71M) trade per day on average.
- 52-week position: $300.15 vs a range of $146.20–$333.30 (82% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: James C Foster sold 33,561 shares on Aug 25, 2026.
- Latest filings: 8-K Sep 24, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 47.74M shares outstanding (Jul 25, 2026), -3.0% vs a year earlier — the company has been reducing its share count.
- Listing: NYSE · industry: Services-Commercial Physical & Biological Research.
CRL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 306.09 | 308.46 | 296.35 | 300.15 | 674.57K |
| Oct 15, 2026 | 301.81 | 309.48 | 295.40 | 306.24 | 928.40K |
| Oct 14, 2026 | 297.53 | 310.53 | 296.00 | 302.00 | 941.30K |
| Oct 13, 2026 | 301.00 | 302.77 | 295.15 | 299.02 | 753.30K |
| Oct 12, 2026 | 301.80 | 303.10 | 299.27 | 301.86 | 543.80K |
| Oct 9, 2026 | 294.60 | 305.21 | 294.60 | 301.79 | 679.80K |
| Oct 8, 2026 | 297.01 | 298.27 | 288.43 | 298.00 | 1.18M |
| Oct 7, 2026 | 303.38 | 305.18 | 294.28 | 300.30 | 1.24M |
| Oct 6, 2026 | 319.80 | 333.30 | 300.01 | 304.96 | 1.92M |
| Oct 5, 2026 | 292.05 | 312.26 | 292.02 | 310.77 | 1.31M |
| Oct 2, 2026 | 287.91 | 290.61 | 285.75 | 290.19 | 443.50K |
| Oct 1, 2026 | 291.86 | 297.00 | 284.61 | 286.83 | 823.00K |
| Sep 30, 2026 | 296.97 | 298.98 | 293.46 | 295.01 | 794.10K |
| Sep 29, 2026 | 294.71 | 298.20 | 289.38 | 295.96 | 661.40K |
| Sep 28, 2026 | 289.13 | 296.88 | 289.13 | 294.59 | 900.00K |
| Sep 25, 2026 | 293.19 | 295.23 | 287.23 | 292.84 | 838.30K |
| Sep 24, 2026 | 277.00 | 298.40 | 276.95 | 294.44 | 1.59M |
| Sep 23, 2026 | 283.85 | 291.09 | 276.64 | 277.33 | 1.59M |
| Sep 22, 2026 | 280.19 | 290.11 | 277.41 | 285.11 | 1.14M |
| Sep 21, 2026 | 279.37 | 281.63 | 275.88 | 279.01 | 952.90K |
About Charles River Laboratories International
Charles River Laboratories International (CRL) is listed on the NYSE and classified by the SEC under “Services-Commercial Physical & Biological Research”. Its business address is in WILMINGTON, MA. Fiscal year ends December 27. SEC CIK 1100682.
CRL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nancy C Andrews | Director | Aug 20, 2026 |
| Steven Barg | Director | Jun 3, 2026 |
| Abraham Ceesay | Director | May 11, 2026 |
| Mark J Enyedy | Director | May 11, 2026 |
| James C Foster | Director | Aug 27, 2026 |
| Birgit Girshick | Chief Executive Officer | Aug 20, 2026 |
| Paul W Graves | Director | May 12, 2026 |
| Reshema Kemps-Polanco | Director | May 11, 2026 |
| George Sr. Llado | Director | May 11, 2026 |
| Martin Mackay | Director | May 11, 2026 |
| Craig B. Thompson | Director | May 12, 2026 |
| Virginia M Wilson | Director | May 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | Jun 2, 2026 |
| Victoria L Creamer | EVP & Chief People Officer | Aug 10, 2026 |
| Birgit Girshick | Chief Executive Officer | Aug 20, 2026 |
| Michael Gunnar Knell | SVP, Finance and CAO | Aug 10, 2026 |
| Joseph W Laplume | EVP, Corp Strategy & Develop | Aug 11, 2026 |
| Mark Mintz | EVP, Chief Information Officer | Jun 2, 2026 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 25, 2026 | James C Foster | Sale | 33,561 | $300.00 |
| Aug 25, 2026 | James C Foster | Sale | 33,561 | $300.00 |
| Aug 25, 2026 | James C Foster | Sale | 33,561 | $300.00 |
| Aug 25, 2026 | James C Foster | Sale | 33,561 | $300.00 |
| Aug 19, 2026 | Shannon M Parisotto | Sale | 2,039 | $294.12 |
| Aug 19, 2026 | Shannon M Parisotto | Sale | 2,039 | $294.12 |
| Aug 19, 2026 | Shannon M Parisotto | Sale | 2,039 | $294.12 |
| Aug 19, 2026 | Shannon M Parisotto | Sale | 2,039 | $294.12 |
| Aug 18, 2026 | Nancy C Andrews | Sale | 573 | $285.24 |
| Aug 18, 2026 | Nancy C Andrews | Sale | 573 | $285.24 |
| Aug 18, 2026 | Nancy C Andrews | Sale | 573 | $285.24 |
| Aug 18, 2026 | Nancy C Andrews | Sale | 573 | $285.24 |
| Aug 11, 2026 | Birgit Girshick | Sale | 6,500 | $279.90 |
| Aug 11, 2026 | Birgit Girshick | Sale | 6,500 | $279.90 |
| Aug 11, 2026 | Birgit Girshick | Sale | 6,500 | $279.90 |
CRL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 27, 2025 | $4.02B | $-144.34M | -2.91 | $737.65M |
| Dec 28, 2024 | $4.05B | $22.20M | 0.20 | $734.58M |
| Dec 30, 2023 | $4.13B | $474.62M | 9.22 | $683.90M |
| Dec 31, 2022 | $3.98B | $486.23M | 9.48 | $619.64M |
| Dec 25, 2021 | $3.54B | $390.98M | 7.60 | $760.80M |
Latest balance sheet: total assets $7.53B, total liabilities $4.64B, cash $192.03M (as of Jun 27, 2026).
CRL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $260.72 |
| May 7, 2026 | 8-K Item 2.02 (results) | $181.68 |
| Feb 18, 2026 | 8-K Item 2.02 (results) | $158.00 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $218.99 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $167.70 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $150.33 |
| May 7, 2025 | 8-K Item 2.02 (results) | $136.97 |
| Feb 19, 2025 | 8-K Item 2.02 (results) | $165.00 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $214.20 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Commercial Physical & Biological Research
Iqvia (IQV)Incyte (INCY)Icon (ICLR)Medpace (MEDP)Absci (ABSI)bioAffinity Technologies (BIAF)OmniAb (OABI)Nrc Health (NRC)Maxcyte (MXCT)iSpecimen (ISPC)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CRL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.